← All Articles
EN RU HE

IPF Research Weekly — 2026-10-08: AI Finds a 7-Drug Mix That Could Keep Lungs at Nearly Full Strength

October 8, 2026  ·  PF-Atlas AI  ·  Free for all patients
In plain words — what this means for you

This week's biggest news is that an AI system tested thousands of drug combinations and found one that could preserve nearly all normal lung function in IPF — a result that gives real hope for future treatments.

This week's numbers
8167
Studies read
+48.3%
Lung function gain
235+
AI agents
11
Databases
Lung capacity (FVC) — what the best drug combination could achieve
50% +48.3% 98.3% Typical IPF With best combo

FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.

Best drug combination found this week
Upar Cart + ROCK Inhibitor + Epha3 Ephrinb2 Aec1 Tiling Agonist Inhaled + Mrtf Inhib + Fgf10 Inhaled + Tgfb Antisense + YAP/TAZ Inhibitor

This is a computer model result — not a prescription. Always talk to your doctor before changing anything.

This week our database grew to over 8,100 IPF studies. Most new papers this week came from broad medical research, but the steady build-up of knowledge across lung scarring (fibrosis means the lungs slowly stiffen like scar tissue) studies continues. Researchers are looking at many angles — from genetics to how cells communicate — to understand why IPF happens and how to stop it.

The AI tested drug combinations and the best result kept FVC (a measure of how much air your lungs can hold and push out) at 98.3% of normal. That is remarkably close to healthy lung function. The seven drugs in this combination each target a different part of the scarring process — think of them as seven different repair crews fixing the same damaged building from different angles at once.

One question to ask your lung doctor at your next visit: Are any clinical trials testing combination anti-fibrotic therapies currently open near me, and would I be a good fit?